Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter 2026

About this update from Nxera Pharma Co., Ltd.

Tokyo, Japan and Cambridge, UK, 7 August 2026 – Nxera Pharma ("the Company" or "Nxera"; TSE: 4565) provides an update on operational activities and reports its consolidated results for the second quarter ended 30 June 2026. The full report can be found here. Chris Cargill, President and CEO of Nxera, commented: "During the second quarter of FY2026, we continued to make steady progress across the business, building on the momentum achieved in the first quarter. Revenues from PIVLAZ® and QUVIVIQ® in Japan continued to increase steadily. For vamorolone, our treatment for Duchenne Muscular Dystrophy, we obtained key regulatory designations in South Korea that support faster patient access. As we work towards submitting a Marketing Authorization Application in South Korea during 2026, we will continue to work closely with the regulatory authorities to bring this medicine to patients in Korea as quickly as possible. "We also made progress across our partnered programs, achieving multiple important revenue-generating milestones. These included the achievement of the second development milestone with Lilly and the third and fourth milestones under our drug discovery collaboration with AbbVie. In addition, we continued to advance the development of new candidates within our proprietary pipeline, as well as related partnering activities. "Further highlighting the value and potential of assets developed using Nxera technology, on 24 June, Lilly completed the acquisition of Centessa Pharmaceuticals. Centessa's orexin receptor agonist programs for the treatment of sleep disorders were jointly created by Centessa and Nxera, and Nxera retains the right to receive future milestone and royalty payments from this pipeline. With Lilly's substantial resources and expertise, we believe the development of this program will be further strengthened. Supported by this continuing momentum and our robust financial position, we remain focused on driving sustained growth and value creation for patients and shareholders in the second half of 2026." Operational Highlights for the first half of FY2026 Progress in Japan and APAC Business Progress with partnered programs Financial Highlights for the Six-month Period ended 30 June 2026 *Convenience conversion to US$ at the following rates: FY 2026: 1US$ =158.15 JPY; FY 2025: 1US$ =148.56 JPY; 30 Jun 2026: 1US$ = 161.94 JPY; 31 Dec 2025: 1U...

View stock analysis, news, and events for Nxera Pharma Co., Ltd.